While approximately 70% of the 452 patients enrolled in ECHELON-2 had systemic anaplastic large-cell lymphoma (sALCL), the FDA label for BV-CHP in the U.S. includes other types of CD30-expressing PTCL. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.